Across TCGA pan-cancer cohorts, TET3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TET3 data layer compared with 28 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TET3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TET3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

LSCC, UCEC, and HNSC are the cancer types where TET3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.877	0.561	.010	16	view →
UCEC	DFS	Median	All	1.000	0.917	.026	2	view →
HNSC	OS	Quartile	All	1.000	0.490	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TET3 tumor-vs-normal RNA expression · all TET3 data types